TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05012826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment in addition to Physiotherapy
Description: Participants in this group will receive OMT in addition to the same interventions of PT group. The frequency of treatment will be decided based on the clinical judgment of the osteopath who is accompanying each case, not exceeding 7 consultations in total. At each visit, the participants will receive a full-body osteopathic examination which include clinical exams, observation, screening tests, palpation, and motion testing. The OMT entail direct (high-velocity low-amplitude; muscle energy; and myofascial release), indirect (functional techniques and balanced ligamentous tension), visceral, and cranial techniques(Giusti, 2017). Selection of specific OMT will follow the 'TART' criteria-Tissue texture changes, Asymmetry, Restriction of motion, Tenderness (Basile et al., 2017; Cerritelli et al., 2011; Giusti R., 2017; Pizzolorusso et al., 2011; Seffinger M.A, 2018).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 8 weeks. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Participants in this group will receive physiotherapy sessions with a maximum frequency of 2 weekly sessions, as defined by the physiotherapist, according to personalized therapeutic plans for a period of 8 weeks. The physiotherapy approach for patients with long COVID includes motor and respiratory rehabilitation aiming at maintaining and/or improving joint mobility, muscle strength, and functional exercise capacity (Thomas et al., 2020). At each visit, the participants respond by self-report about their general condition. Depending on the case, the physiotherapist will perform a reevaluation with specific tests. The PT group will receive physiotherapy treatment offered by five physiotherapists, with more than 5 years of experience each, duly registered with their class council.
Study: NCT05263310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prepare for Your Diabetes Care
Description: Educational video and Action Plan handout

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Control arm patients will continue with usual care
Study: NCT06473012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Caregivers of Older Adults
Description: Cognitive Behavioral Therapy Intervention for Caregivers of Older Adults is designed to be implemented in a group setting with 12 to 15 caregivers in a group. It consists of 6 weekly sessions, and each session lasts for 90 minutes to 120 minutes. The content of the intervention is based on lifestyle intervention, CBT and effective communication skills. Home practices will be assigned to the participants in between each weekly session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention for Caregivers of Older Adults
Description: The control group receives 6 weekly education sessions on useful healthcare information (mental health, physical health, health ageing and dementia). Each session lasts for 90 minutes to 120 minutes.
Study: NCT05336032

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food (rice)
Description: Cooked rice with 75 gm carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food (rice)
Description: Cooked rice with 75 gm carbohydrate
Study: NCT05659693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: digital literacy education specific to menopause
Description: Education; It is planned as 5 sessions in the form of presentation, homework, scenario and sending reminder messages. The training is planned to last approximately 20 minutes with a power point presentation prepared by the trainer. The survey will be evaluated in the first session. Women will be told what digital literacy is, why it is important, how to verify information and resources, security of accounts, resources, money and devices, access to information, understanding and valuing information. A screening and access to information session will be held with a scenario prepared on menopausal symptoms, taking into account the variables of information and resource security, access to information, understanding and valuing information, with examples on the digital platform. The woman will be given a scenario homework on menopausal symptoms. Interim evaluation will be made in the fourth week of the training. The final evaluation will be made in the fifth session.
Study: NCT06040151

Intervention type: DEVICE
Intervention: Digizorg mobile app (quality evaluation study)
Description: Erasmus Medical Center is developing a state-of-the-art, mobile-based patient portal that combines up-to-date medication lists from all healthcare providers involved in a patient's care. Other functionalities include: accessing health information, viewing and planning appointments, teleconsulting, sending messages, filling in questionnaires, reporting self-measurements, and reading background information on diseases, medication, and other interventions. The patient portal will primarily be implemented in Erasmus Medical Center, and is ultimately intended for every patient, regardless of underlying condition.
Study: NCT06192056

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RNT Focused Web- Based Self-Help Program
Description: This 10 day long intervention contains psychoeducational contents, experimental exercises, monitoring behavior and committed action strategies. Each step of the intervention aims to develop a specific psychological flexibility skill like cognitive defusion etc.
Study: NCT05931653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physical therapy
Description: • Multimodal Physical therapy: Hot pack for 15 mins, TENS for 15 mins, Ultrasound at 1.5 W/cm2 intensity for 5 mins, Soft tissue release for \<5-15 mins as per need, HVLA, PA Glides (Central and Transverse mobilizations) (10 sec each) x5 sets, Lumbar facet gapping (LFG) in side lying (10 sec 3 sets) and Lumbar rotational facet gapping (LRFG) in side lying (10 sec 3 sets). 03 days/week for 06 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training along with and Multimodal Physical therapy
Description: * Multimodal Physical Therapy: Hot pack-5 mins, TENS-5 mins, U.S (1.5 W/cm2)-5 mins, Soft tissue release-\<5-15 mins, HVLA, PA Glides (Central and Transverse)-10 sec each 5 sets, Lumbar facet gapping-10 sec 3 sets and Lumbar rotational facet gapping-10 sec 3 sets. 3 days/week for 6 weeks.~* Proprioceptive Training:1. Trunk Balance (15 mins). In sitting, kneeling, quadruped, and supine positions for 30 seconds to 2 minutes. Progression to more challenging. Each will be performed for 2-3 mins. In case of pain exercise will be interrupted and substituted with another one.~  2. PNF Training (10-12 mins). Each PNF training-1 set of 15 reps with 30s rest between and 60s after 15 reps. Week 1-2 alternate full isometrics of trunk flexors and extensors for 10s in sitting. Week 3-4, 5s resisted concentric, 5s eccentric and 5s isometrics contractions in forward and backward bending. Week 5-6, alternate chop and lift movement patterns of upper extremities in diagonal and spiral directions for 10s.
Study: NCT04429308

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy
Description: Photodynamic Therapy consists of (Levulan Kerastick (aminolevulinic acid HCL) topical solution, 20% + BLU-U Photodynamic Light Therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemical Peels
Description: Chemical peels consists of a combination of Jessner's Solution: Composed of Salicylic Acid (14%), Medical Grade Lactic Acid (14%), Medical Grade Resorcinol (14%), Denatured Ethyl Alcohol AND 35% Trichloroacetic acid peels
Study: NCT05248165

Intervention type: DEVICE
Intervention: PCI
Description: Percutaneous coronary intervention
Study: NCT06287138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofol
Description: Ciprofol will be infused at 0.3，0.4，0.5，0.6，0.7，0.8 mg/kg/h in sequence for 30 minutes at each dose.
Study: NCT05716425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: STI-1558 will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 600 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STI-1558 placebo
Description: STI-1558 placebo will be orally administered under fasting condition twice daily (BID) for 5 days (10 doses in total) at a dose of 0 mg, respectively; the two doses administered will be at a minimum interval of 8 hours (≥8 h). Efficacy and safety will be assessed until D29 after the first dose.
Study: NCT05681715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Rozanolixizumab self-administration via Syringe Driver or Manual Push.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Rozanolixizumab self-administration via Syringe Driver or Manual Push.
Study: NCT05314088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE+
Description: The intervention includes psychoeducational videos and written activities on topics such as coping strategies, cognitive appraisals, the responsibility model, and social connections, all integrated into the overarching process of resilience.
Study: NCT06392542

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Selves
Description: Whole Selves is a brief online self-guided intervention addressing transgender/nonbinary young adults' experiences with alcohol use and romantic relationships. The intervention is delivered in a single session of approximately 40 minutes. Whole Selves employs principles of technology-adapted motivational interviewing (e.g., eliciting and strengthening participants' internal reasons for behavior change through interactive activities) as well as personalized feedback on participants' self-reported alcohol use and romantic relationship experiences. The intervention incorporates text and video narratives from transgender/nonbinary people sharing their own experiences with alcohol use and romantic relationships. Content will be tailored based on participants' current alcohol use and romantic relationship experiences.
Study: NCT05945654

Intervention type: PROCEDURE
Intervention: Anastomotic Leak after Ivor Lewis Oesophagectomy
Description: Surgical resection of the esophagus with oesophagogastrostomy. Groups depend on postoperative complication
Study: NCT05314088

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stress Reduction Control
Description: Placebo Comparator: Stress Reduction Control Control participants will complete an attention-matched internet stress reduction paradigm, which includes an internet navigation protocol and placebo computer games.
Study: NCT06412783

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood test
Description: performing blood tests on the participants for specific markers.
Study: NCT05800067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axi-cel
Description: Axicabtagene ciloleucel (Axi-cel) is an autologous anti-CD-19 chimeric antigen receptor(CAR) T-cell therapy approved by FDA in 2017 for the treatment of patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). Now, it is the standard treatment for these patients recommended by NCCN and other guidelines. Axi-cel was approved for R/R LBCL patients who had received 2 or more prior lines of therapy on 2021 June in China.
Study: NCT05314192

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary test
Description: saliva was assessed for MIP-1 alpha

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary test
Description: saliva was assessed for MIP-1 alpha

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary test
Description: saliva was assessed for MIP-1 alpha

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary test
Description: saliva was assessed for MIP-1 alpha

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary test
Description: saliva was assessed for IL-6

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary test
Description: saliva was assessed for IL-6

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary test
Description: saliva was assessed for IL-6

Intervention type: DIAGNOSTIC_TEST
Intervention: salivary test
Description: saliva was assessed for IL-6
Study: NCT05754060

Intervention type: OTHER
Intervention: Saint-Louis Lille Battery (SSLIB)
Description: Saint-Louis Lille Battery (SSLIB) composed of three tests studying the speed of cognitive processing and proposed to the subjects on a tactile tablet. These three tasks are:~(a) Reaction time tasks specifically developed for this study b) A digital adaptation of the WAIS-IV code subtest c) A digital version of the Trail Making Test (A and B)
Study: NCT05996614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP in skin grafts
Description: topical application of platelet rich plasma before resurfacing with STSG in Post burn raw areas

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional methods in skin grafts
Description: fixation of the graft with stitches and staplers
Study: NCT05162742

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: ATC: M04AC01

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT05004974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is administered every 3 weeks (200mg, IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib 13.5 mg once daily (QD) orally, continuous administration.
Study: NCT06508372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical thymoquinone Ointment
Description: One plaque per patient on one side of the body will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical placebo ointment
Description: In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.
Study: NCT05551975

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Product
Description: Fed from Study Day 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Product 1
Description: Fed from Study Day 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Product 2
Description: Fed from Study Day 1
Study: NCT04988282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Tablet
Description: Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone Tablet
Description: Methylprednisolone, oral, 0.5 mg/kg/day, 4 weeks
Study: NCT04262232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Ca-HELP for Geriatric Cancer Patients
Description: Intervention group: This intervention will be informed by social-cognitive theory10-13 and modeled after the tailored education and coaching intervention (TEC) used for Ca-HELP previously and consists of six components: (1) Assessment of current knowledge, attitudes, and preferences; (2) clarification and correction of misconceptions about cancer pain control; (3) teaching of relevant concepts (education about cancer pain control); (4) planning (identifying goals of care, creating achievable goals of care, and creating strategies to communicate goals of care to providers and family members); (5) rehearsal of communication strategies using role play exercises; and (6) portrayal of learned skills (patient applies skills in visit with healthcare provider).
Study: NCT06507449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lithotripsy
Description: Calcified lesion preparation using lithotripsy before implantation of a drug-eluting stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orbital atherectomy
Description: Calcified lesion preparation using orbital atherectomy before implantation of a drug-eluting stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-pressure non-compliant balloon
Description: Calcified lesion preparation using high-pressure non-compliant balloon before implantation of a drug-eluting stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Optical coherence tomography assessment of coronary arteries.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Optical coherence tomography assessment of coronary arteries.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Description: Optical coherence tomography assessment of coronary arteries.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
Description: A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
Description: A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
Description: A coronary thermodilution system used for evaluate differences between the impact of calcified lesion preparation methods on coronary microvascular function.
Study: NCT06336694

Intervention type: PROCEDURE
Intervention: surgery or diagnostic staging laparoscopy
Description: diagnosis of PDAC with peritoneal examination based on the surgical (for tumors treated with surgery) or diagnostic staging laparoscopy findings (for tumors treated with radiotherapy/chemotherapy)

Intervention type: PROCEDURE
Intervention: surgery or diagnostic staging laparoscopy
Description: diagnosis of PDAC with peritoneal examination based on the surgical (for tumors treated with surgery) or diagnostic staging laparoscopy findings (for tumors treated with radiotherapy/chemotherapy)
Study: NCT05779280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THDA + Acetyl Zingerone Topical Product
Description: A skin care product with Acetyl Zingerone (Synoxyl® AZ) and THDA (VitaSynol® C) used twice daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THDA
Description: A skin care product with THDA (VitaSynol® C) used twice daily
Study: NCT04935229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 doses will be delivered via hepatic artery infusion using pressure enabled drug delivery using the TriNav device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: During Cohort B, nivolumab will be administered together with SD-101 and during Cohort C, it will be administered with ipilimumab and SD-101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: During Cohort C, ipilimumab will be administered together with nivolumab and SD-101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab and Relatlimab
Description: During optional Cohort C1, nivolumab and relatlimab will be administered with SD-101
Study: NCT05503511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT 2042 (bumetanide analog) or Matching Placebo
Description: Soft gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT 2042 (bumetanide analog) or Matching Placebo
Description: Soft gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT 2042 (bumetanide analog) or Matching Placebo
Description: Soft gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT 2042 (bumetanide analog) or Matching Placebo
Description: Soft gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT 2042 (bumetanide analog) or Matching Placebo
Description: Soft gelatin capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT 2042 (bumetanide analog) or Matching Placebo
Description: Soft gelatin capsules
Study: NCT05513391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant influenza vaccine (RIV4)
Description: Pharmaceutical form: solution for injection Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent influenza vaccine (IIV4)
Description: Pharmaceutical form: suspension for injection Route of administration: intramuscular
Study: NCT05538078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozone gel
Description: application of Ozone gel after scaling by ultrasonic scaler in the bottom of periodontal pocket

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone gel
Description: application of Ozone gel after scaling by ultrasonic scaler in the bottom of periodontal pocket